financetom
Business
financetom
/
Business
/
Smucker's Stock Drops Amid Q4 Sales Miss, FY26 Profit Outlook Disappoints
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Smucker's Stock Drops Amid Q4 Sales Miss, FY26 Profit Outlook Disappoints
Jun 10, 2025 8:03 AM

J.M. Smucker Company’s shares are trading lower on Tuesday after it reported fourth-quarter adjusted earnings per share of $2.31, beating the analyst consensus estimate of $2.24.

Quarterly sales of $2.14 billion (down 3% year over year) missed the Street view of $2.18 billion.

Excluding $45.9 million of noncomparable net sales in the prior year related to divestitures and $3.9 million of unfavorable foreign currency exchange, net sales decreased $12.1 million, or 1%.

Also Read: US Stocks Mixed; JM Smucker Shares Plunge After Q4 Results

Adjusted operating income slumped 8% on a year-over-year basis to $422.4 million. Adjusted gross profit decreased $84.2 million, or 9%.

The decrease in comparable net sales reflects a three percentage point decrease from volume/mix, primarily driven by decreases for dog snacks, sweet baked goods, and lower contract manufacturing sales.

The company exited the quarter with cash and equivalents worth $69.9 million. Inventories totaled $1.209 billion.

Long-term debt (less current portion) increased to $7.036 billion, up from $6.773 billion a year ago. Net debt repayments in the quarter totaled $177.6 million.

Outlook: J.M. Smucker forecasts fiscal year 2026 adjusted earnings per share between $8.50 and $9.50, falling below the analyst consensus of $10.26.

The company also anticipates net sales to increase by 2% to 4% for the upcoming fiscal year.

Price Action: SJM shares are trading lower by 11.1% to $99.03 at last check Tuesday.

Read Next:

US Stocks Likely To Open Lower: Equities Face ‘High Bar’ Amid Tariff-Fueled Volatility In The Second Half Of 2025, Says Analyst

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Battery Future Acquisition Enters Merger Agreement With Class Over
Battery Future Acquisition Enters Merger Agreement With Class Over
May 14, 2024
11:01 AM EDT, 05/14/2024 (MT Newswires) -- Battery Future Acquisition ( BFAC ) has entered into a merger agreement with Class Over that values the educational technology platform at about $135 million, the companies said Tuesday. The deal would provide Class Over gross proceeds of about $56 million at closing and lead to Class Over's expected listing on the New...
Satellos Bioscience Q1 Loss Widens Due To Higher Expenses; But Says
Satellos Bioscience Q1 Loss Widens Due To Higher Expenses; But Says "On track" to initiate Phase 1 First-in-human Clinical Trials Mid-2024
May 14, 2024
11:01 AM EDT, 05/14/2024 (MT Newswires) -- Satellos Bioscience Inc. ( MSCLF ) , a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, earlier on Tuesday reported a first-quarter net loss of $6.9 million, or $0.06 per share, wider than a loss $1.7 million, or $0.04 per share, a year...
Germany's PBB reports slight gain in quarterly profit, risk provisions rise
Germany's PBB reports slight gain in quarterly profit, risk provisions rise
May 14, 2024
FRANKFURT, May 14 (Reuters) - Deutsche Pfandbriefbank (PBB), one of Germany's top property financiers, posted a slight rise in first-quarter profit and an increase in risk provisions as it navigates troubles in the real-estate industry. The bank's quarterly profit was 29 million euros ($31.27 million), compared with 27 million a year earlier, while provisions for loan losses shot up to...
Centogene, Evotec Discover New Molecule for Potential Gaucher Disease Treatment
Centogene, Evotec Discover New Molecule for Potential Gaucher Disease Treatment
May 14, 2024
11:04 AM EDT, 05/14/2024 (MT Newswires) -- Centogene ( CNTG ) said Tuesday that the company and partner Evotec (EVO) discovered a new small molecule that has the potential to treat patients with type-2 and type-3 Gaucher disease, or neuronopathic Gaucher disease. The companies have extended their collaboration for another year, granting Evotec a research and development license for the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved